Tags

Type your tag names separated by a space and hit enter

Monochromatic excimer light 308 nm in monotherapy and combined with topical khellin 4% in the treatment of vitiligo: a controlled study.
Dermatol Ther. 2009 Jul-Aug; 22(4):391-4.DT

Abstract

Vitiligo is an acquired depigmentation disorder affecting 1-4% of the world's population. Conventional therapies include steroids, photosensitive topical agents, surgical treatments, and phototherapy. The aim of the study was to evaluate the efficacy of monochromatic excimer light 308 nm (MEL), both as a monotherapy and in combination with khellin 4% ointment in vitiligo. Forty-height patients (36 male and 12 female) affected with vitiligo were enrolled in this open prospective study. Patients were selected and divided into three groups: group I included 16 patients treated with MEL 308 nm once-weekly and oral vitamin E; group II included 16 patients treated with MEL 308 nm once-weekly combined with khellin 4% ointment (MEL-K) and oral vitamin E; group III (control group) included 16 patients treated only with oral vitamin E. Efficacy was assessed at the end of 12 weeks based on the percentage of repigmentation. Group I (MEL-group) showed a moderate repigmentation in 2/16 (12.5%) patients, good repigmentation in 10/16 (62.5%), and excellent repigmentation in 4/16 (25%) patients. Group II (MEL-K group) presented moderate repigmentation in 2/16 (12.5%) patients, good repigmentation in 5/16 (31.25%), and excellent repigmentation in 9/16 (56.25%). Group III (control group) showed a moderate repigmentation in 3/16 patients (18.75%), a good repigmentation in 1/16 (6.25%) patient, while 10/16 (62.5%) patients did not show signs of repigmentation. The clinical response achieved in group I and II was higher compared with group III (control group) without showing significant differences. MEL 308 nm, alone and/or combined with khellin 4% offered encouraging results and it may be considered a valid therapeutic option worthy of consideration in the treatment of vitiligo.

Authors+Show Affiliations

Department of Dermatology, University of Rome Tor Vergata, Rome, Italy. rositasaraceno@yahoo.itNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Controlled Clinical Trial
Journal Article

Language

eng

PubMed ID

19580584

Citation

Saraceno, Rosita, et al. "Monochromatic Excimer Light 308 Nm in Monotherapy and Combined With Topical Khellin 4% in the Treatment of Vitiligo: a Controlled Study." Dermatologic Therapy, vol. 22, no. 4, 2009, pp. 391-4.
Saraceno R, Nisticò SP, Capriotti E, et al. Monochromatic excimer light 308 nm in monotherapy and combined with topical khellin 4% in the treatment of vitiligo: a controlled study. Dermatol Ther. 2009;22(4):391-4.
Saraceno, R., Nisticò, S. P., Capriotti, E., & Chimenti, S. (2009). Monochromatic excimer light 308 nm in monotherapy and combined with topical khellin 4% in the treatment of vitiligo: a controlled study. Dermatologic Therapy, 22(4), 391-4. https://doi.org/10.1111/j.1529-8019.2009.01252.x
Saraceno R, et al. Monochromatic Excimer Light 308 Nm in Monotherapy and Combined With Topical Khellin 4% in the Treatment of Vitiligo: a Controlled Study. Dermatol Ther. 2009 Jul-Aug;22(4):391-4. PubMed PMID: 19580584.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Monochromatic excimer light 308 nm in monotherapy and combined with topical khellin 4% in the treatment of vitiligo: a controlled study. AU - Saraceno,Rosita, AU - Nisticò,Steven P, AU - Capriotti,Elisabetta, AU - Chimenti,Sergio, PY - 2009/7/8/entrez PY - 2009/7/8/pubmed PY - 2009/9/17/medline SP - 391 EP - 4 JF - Dermatologic therapy JO - Dermatol Ther VL - 22 IS - 4 N2 - Vitiligo is an acquired depigmentation disorder affecting 1-4% of the world's population. Conventional therapies include steroids, photosensitive topical agents, surgical treatments, and phototherapy. The aim of the study was to evaluate the efficacy of monochromatic excimer light 308 nm (MEL), both as a monotherapy and in combination with khellin 4% ointment in vitiligo. Forty-height patients (36 male and 12 female) affected with vitiligo were enrolled in this open prospective study. Patients were selected and divided into three groups: group I included 16 patients treated with MEL 308 nm once-weekly and oral vitamin E; group II included 16 patients treated with MEL 308 nm once-weekly combined with khellin 4% ointment (MEL-K) and oral vitamin E; group III (control group) included 16 patients treated only with oral vitamin E. Efficacy was assessed at the end of 12 weeks based on the percentage of repigmentation. Group I (MEL-group) showed a moderate repigmentation in 2/16 (12.5%) patients, good repigmentation in 10/16 (62.5%), and excellent repigmentation in 4/16 (25%) patients. Group II (MEL-K group) presented moderate repigmentation in 2/16 (12.5%) patients, good repigmentation in 5/16 (31.25%), and excellent repigmentation in 9/16 (56.25%). Group III (control group) showed a moderate repigmentation in 3/16 patients (18.75%), a good repigmentation in 1/16 (6.25%) patient, while 10/16 (62.5%) patients did not show signs of repigmentation. The clinical response achieved in group I and II was higher compared with group III (control group) without showing significant differences. MEL 308 nm, alone and/or combined with khellin 4% offered encouraging results and it may be considered a valid therapeutic option worthy of consideration in the treatment of vitiligo. SN - 1529-8019 UR - https://www.unboundmedicine.com/medline/citation/19580584/Monochromatic_excimer_light_308_nm_in_monotherapy_and_combined_with_topical_khellin_4_in_the_treatment_of_vitiligo:_a_controlled_study_ L2 - https://doi.org/10.1111/j.1529-8019.2009.01252.x DB - PRIME DP - Unbound Medicine ER -